Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : Mundipharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The two companies have entered into a collaboration agreement to continue the development work of incorporating an environmentally friendly propellant into the formulation of flutiform® (fluticasone propionate/formoterol fumarate) used in a pMDI.
Brand Name : Flutiform
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : Mundipharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cannabidiol,Isoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicolog...
Brand Name : IHL-216A
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Cannabidiol,Isoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : IPA-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inspira
Deal Size : Undisclosed
Deal Type : Agreement
Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment
Details : IPA-001 is inhaled formulation displayed viricidal activity against SARS-CoV2 after 5 minutes contact time. It is purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 ...
Brand Name : IPA-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 06, 2021
Lead Product(s) : IPA-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inspira
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Vectura Highlights Update Made by Hikma on Launch of Generic Advair Diskus®
Details : Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.
Brand Name : Fluticasone Propionate/Salmeterol-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 21, 2021
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : $95.0 million
Deal Type : Agreement
Vectura Earns $11m Milestone as Hikma Receives US FDA Approval for Generic Advair Diskus®
Details : The new device is an evolution of Vectura’s lever-operated multi-dose (LOMI) device and builds on Vectura and Hikma’s shared experience with the generic Advair Diskus® programme, enabling accelerated development under this agreement.
Brand Name : Fluticasone Propionate/Salmeterol-Generic
Molecule Type : Small molecule
Upfront Cash : $15.0 million
December 17, 2020
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : $95.0 million
Deal Type : Agreement
Lead Product(s) : VR588
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Kinaset Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.
Brand Name : VR588
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : VR588
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Kinaset Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Fluticasone Propionate / Salmeterol or VR315 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.
Brand Name : VR315
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Sponsor : Monash University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 14, 2020
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Sponsor : Monash University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
QVM149 Receives Regulatory Approval in Europe and Japan
Details : QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.
Brand Name : Enerzair Breezhaler
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Aerami
Deal Size : Undisclosed
Deal Type : Agreement
Vectura Signs Agreement with Aerami Therapeutics Inc
Details : Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 08, 2020
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Aerami
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Market Place
Reset All
